Format

Send to

Choose Destination
Drugs. 2018 Mar;78(3):389-396. doi: 10.1007/s40265-018-0877-7.

Netarsudil Ophthalmic Solution 0.02%: First Global Approval.

Author information

1
Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Abstract

Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa®] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

PMID:
29453668
DOI:
10.1007/s40265-018-0877-7

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center